Evaluation of Nephure™, and the Reduction of Dietary Oxalate, in Healthy Volunteers

NCT ID: NCT03661216

Last Updated: 2018-09-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 33 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-07-11
• Study Completion Date: 2018-08-05

Brief Summary

The purpose of this double-blind study is to determine the effect of reducing oxalates in the diet of healthy volunteers by using Nephure, an oxalate-reducing enzyme, as compared to placebo.

Detailed Description

This study aims at evaluating the effect from Nephure in reducing dietary oxalate in healthy volunteers on a controlled diet as compared to placebo. Subjects are on a normal diet with controlled oxalate (750mg/day) and calcium (550mg/day) levels for 8 consecutive days. The study is a cross-over design with two four-day treatment periods. The study intends to determine level of reduction in urinary oxalate output as a measure of the effect of Nephure on dietary oxalate when ingested with a meal.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo

3g of non-GMO maltodextrin

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

3g of non-GMO maltodextrin is mixed with 8oz of water and ingested with breakfast, lunch and dinner.

Nephure

3g of Nephure

Group Type: ACTIVE_COMPARATOR

Nephure Oxalate-reducing Enzyme

Intervention Type: DIETARY_SUPPLEMENT

3g of Nephure is mixed with 8oz of water and ingested with breakfast, lunch and dinner.

Interventions

Nephure Oxalate-reducing Enzyme

3g of Nephure is mixed with 8oz of water and ingested with breakfast, lunch and dinner.

Intervention Type: DIETARY_SUPPLEMENT

Placebo

3g of non-GMO maltodextrin is mixed with 8oz of water and ingested with breakfast, lunch and dinner.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Subject has granted written informed consent.

2. Subject must be a male or non-pregnant female, at least 18 to 55 years of age at the time of Screening, and non-smoker for at least 3 months at the time of screening and throughout study.

3. Subject has a BMI of 18.5 - 29.9 kg/m2 at the time of Screening.

4. Subject has an estimated glomerular filtration rate (eGFR) of >90 mL/min/1.73 m2 at the time of Screening (GFR is calculated using the NIDDK provided equation at the following web address: www.niddk.nih.gov/health-information/communication-programs/nkdep/laboratory-evaluation/glomerular-filtration-rate-calculators/ckd-epi-adults-conventional-units.)

5. Subject has a urinary oxalate <40.5mg/24 hours at the time of Screening .

6. Subject has a urinary uric acid <750mg/24hour at the time of Screening1.

7. Subject is in good health as determined by complete physical examination, medical history, vital signs, and laboratory tests.

8. Subject is able to understand the study and be able to comply to the requirements and restrictions, including agreeing to complete the 24-hour urine collections, and has the ability to report their symptoms.

9. Subject is able to comply with all dietary expectations and fluid intake at the discretion of the Principal Investigator (PI).

10. Female subjects must agree to use an acceptable form of birth control from screening through the duration of the study (unless otherwise stated). See section 5.1.1.

Exclusion Criteria

1. Subject has a history or presence of clinically significant cardiovascular, pulmonary, respiratory, digestive, hepatic, renal, hematological, gastrointestinal (e.g., active bowel disease, known gallstones, GERD, etc.), endocrine, metabolic, immunological, infectious, dermatologic, neurological, psychological, or psychiatric disease or gastrointestinal surgeries (e.g., bowel resection, gastric bypass, cholecystectomy within the 6 months prior to screening, etc.), in the opinion of the Principal Investigator.

2. Subject has received a positive result for urine drug screen at the screening visit or on Day -3, or has a history of positive test result(s) for human immunodeficiency virus (HIV) antibody, Hepatitis B surface antigen or Hepatitis C antibody.

3. Subject has a history of or a current clinically significant medical condition, allergy, food sensitivity (e.g. maltodextrin) or surgical intervention that might significantly compromise the safety of the subject, interfere with study assessments, or impact the validity of the study results, in the opinion of the Principal Investigator.

4. Subject is taking a medication that would indicate significant anxiety, depression, serious or unstable illness, or lack of good general health, that could interfere with the subject's ability to adhere to study instructions, or complete the study, in the opinion of the Principal Investigator and with approval of the Sponsor.

5. Subject is unable or unwilling to discontinue use of dietary supplements (vitamins, minerals, and/or supplements) throughout the duration of the study or has used these products within 7 days prior to screening.

6. Subject has continuously used (not including intermittent or rare PRN use) prescription or over the counter: proton pump inhibitors within 12 weeks of screening; or H2 blockers within 6 weeks of screening; or antacids within 2 weeks of screening.

7. Subject is currently using medication that could affect oxalate handling such as cholestyramine, any carbonic anhydrase inhibitor, any steroid, any diuretic, any immunosuppressant drug, or has received chemotherapy or systemic immunosuppressive drugs within 6 mos. of their screening visit.

8. Subject has had a clinically significant surgical procedure within 3 mos. prior to the Screening visit or planned surgical procedure during the study conduct.

9. Subject has received an investigational product, device, or therapy within 30 days prior to screening.

10. Subject has been on a self-restricted, controlled, or special therapeutic diet, or has had substantial changes in eating or bowel habits, or have had new GI complaints, within 30 days of their screening visit.

11. Subject has been on systemic antibiotic therapy within 6 weeks prior to the screening visit or plans antibiotic therapy during the study conduct.

12. Subject has a history of allergy or hypersensitivity to the study products, its excipients or any comparable products or excipients.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Captozyme, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Donald Burkindine, D.O.

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

QPS Bio-Kinetic Clinical Applications, LLC

Springfield, Missouri, United States

Countries

United States

References

Cowley H, Yan Q, Koetzner L, Dolan L, Nordwald E, Cowley AB. In vitro and in vivo safety evaluation of Nephure. Regul Toxicol Pharmacol. 2017 Jun;86:241-252. doi: 10.1016/j.yrtph.2017.03.016. Epub 2017 Mar 18.

Reference Type: BACKGROUND

PMID: 28322893 (View on PubMed)

Quintero E, Bird VY, Liu H, Stevens G, Ryan AS, Buzzerd S, Klimberg IW. A Prospective, Double-Blind, Randomized, Placebo-Controlled, Crossover Study Using an Orally Administered Oxalate Decarboxylase (OxDC). Kidney360. 2020 Sep 3;1(11):1284-1290. doi: 10.34067/KID.0001522020. eCollection 2020 Nov 25.

Reference Type: DERIVED

PMID: 35372879 (View on PubMed)

Other Identifiers

95318

Identifier Type: -

Identifier Source: org_study_id